Share on StockTwits

Illumina (NASDAQ:ILMN) SVP Nicholas Naclerio sold 2,000 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $169.77, for a total value of $339,540.00. Following the completion of the sale, the senior vice president now directly owns 25,781 shares of the company’s stock, valued at approximately $4,376,840. The sale was disclosed in a document filed with the SEC, which is available at this link.

Illumina (NASDAQ:ILMN) opened at 170.16 on Thursday. Illumina has a 52-week low of $48.00 and a 52-week high of $173.98. The stock’s 50-day moving average is $139.9 and its 200-day moving average is $101.0. The company has a market cap of $21.561 billion and a P/E ratio of 189.33.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, January 28th. The company reported $0.45 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.44 by $0.01. The company had revenue of $387.00 million for the quarter, compared to the consensus estimate of $382.06 million. During the same quarter last year, the company posted $0.42 earnings per share. Illumina’s revenue was up 25.1% compared to the same quarter last year. Analysts expect that Illumina will post $2.06 EPS for the current fiscal year.

A number of analysts have recently weighed in on ILMN shares. Analysts at UBS AG raised their price target on shares of Illumina from $152.00 to $202.00 in a research note on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Bank of America raised their price target on shares of Illumina from $165.00 to $190.00 in a research note on Tuesday. Finally, analysts at Leerink Swann set a $160.00 price target on shares of Illumina in a research note on Wednesday, January 29th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $123.41.

Illumina, Inc (NASDAQ:ILMN) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.